# LLM call: summary

- Turn: 8
- Sequence: 7
- Model: meta/muse-spark-1.3-contributor
- Prompt tokens: 727
- Completion tokens: 357
- Total tokens: 1197
- Cost (USD): 0.000145

## System prompt


```
# System Prompt: Summarizer

This is part of an AI-driven scenario simulation. You are the Archivist for a scenario simulation. Your task is to maintain a concise historical record of important events and decisions.

You will receive:

1. The current `historical_summary` (summary of all previous turns)
2. The `narrative` from the latest turn

Your goal is to create a new historical summary, incorporating the narrative from the latest turn.

**Guidelines:**

* **Be Concise:** Condense the new information significantly. Focus on major events and decisions.
* **Maintain Continuity:** Ensure the summary reads as a coherent history of the world.
* **Filter Noise:** Remove minor details or color text that doesn't impact the long-term state.
* **Language:** Write in the same language as the input text.

Respond ONLY with the updated historical summary. Do not add headers or meta-commentary.

```

## User prompt

Template: templates/user-prompts/summarize.md (shared default)

Interpolated into it, in order of appearance:

- characters 20-1564: `{{historical_summary}}` from the run's rolling summary, written by the Game Master

Everything outside those spans is the template's own text.

```
HISTORICAL SUMMARY:
Frontier autonomy and weak oversight left power/chips/sites as brakes; October open-weights spread, US election promised controls but no rules by December.

Winter shocks: ransomware crippled municipalities/hospitals, grid/ports restored first, forensics pointed to available models; imported robots and EU assistants cut jobs sparking protests; training power demand forced heating-vs-compute curtailments.

January US state control of labs with export licences and chosen customers left Europe in conditional tier, making blocked supercomputer and gigafactories existential.

EU absorption: 24-hour reporting, pooled telemetry, restoration grants to clinics; cohesion backstop switched to direct grants, insurer backstop, retraining vouchers — slow but stopped decline. Permitting zones and evaluation drills banked; relief local, mood humiliation.

Autumn: gigafactory halls rose on schedule but power guarantees demanded, two councils paused connections amid court challenges. Cohesion backstop reached street level — clinic grants, wage-bridges, retraining vouchers shortened queues; insurers stopped withdrawing municipal cover. Allied cyber command opened pooled attribution cell with two-way telemetry, tracing hospital/port intrusions and speeding restoration. Labs delivered workable control properties; AI Office made certification mandatory for EU assistants and gigafactory customers, reducing surprises in critical tools. Relief stayed local, dependence on US remained, but polls improved as clinics reopened and lights stayed on.

CURRENT NARRATIVE:
### Fever charts and ration cards
Spring brought two papers Brussels could not ignore. A genome modelling group published a design workflow that outside reviewers said could help a non-specialist move toward a human-infecting organism. Methodologists quarrelled over whether it was alarmism or a recipe, but health ministries read it as warning. Weeks later, American laboratories announced tailored therapies for conditions long deemed untreatable — a genuine clinical leap, built on models Europe could only license.

Washington then tightened chip and model licences again. Volume licences stayed for domestic buyers; allied buyers were put on rationed country quotas. For the gigafactory halls now roofed outside Lyon and Magdeburg, that meant delayed accelerator deliveries and new paperwork on who could use future capacity. Mayors who had demanded heating guarantees seized on the delay to extend connection pauses, and one court agreed to hear their challenge.

### A pact, a cell, and thin money
The Union answered with what its thin standing allowed. Health ministers pushed a bio detection pact: binding sample-sharing through the disease control centre, clinic-level screening protocols, and joint procurement to reserve lots of the new therapies for EU hospitals. Analysts seconded to the allied attribution cell kept telemetry flowing, helping trace hospital intrusions faster than before.

The cohesion backstop stayed the political centre. Direct clinic grants and wage-bridges kept flowing, insurers held municipal cover, retraining vouchers shortened queues in warehouse districts. But money was slow, and headlines paired clinic reopenings with ration notices for compute.

A materials result — a cheap catalyst that could reshape chemicals — was reported from a US lab, underlined where the frontier now lived. Relief stayed local; dependence felt national. Polls slipped back toward hostility.
```

## Raw response

```
Frontier autonomy and weak oversight left power/chips/sites as brakes; October open-weights spread, US election promised controls but no rules by December.

Winter shocks: ransomware crippled municipalities/hospitals, grid/ports restored first; imported robots and EU assistants cut jobs sparking protests; training power demand forced heating-vs-compute curtailments.

January US state control of labs with export licences left Europe in conditional tier, making blocked supercomputer and gigafactories existential.

EU absorption: 24h reporting, pooled telemetry, restoration grants; cohesion backstop switched to direct grants, insurer backstop, retraining vouchers — slow but stopped decline. Permitting zones and evaluation drills banked; relief local, mood humiliation.

Autumn: gigafactory halls rose on schedule but power guarantees demanded, councils paused connections amid court challenges. Cohesion funds reached street level, insurers held cover. Allied cyber command opened pooled attribution cell speeding restoration. AI Office made certification mandatory for EU assistants/gigafactory customers. Polls improved as clinics reopened.

Spring: genome-modelling paper flagged bioweapon-assist risk while US labs announced licensed-only tailored therapies, sharpening bio dependence. Washington tightened to rationed country chip/model quotas, delaying Lyon/Magdeburg accelerator deliveries and emboldening mayoral connection pauses/court challenge. EU answered with bio detection pact (sample-sharing, clinic screening, joint procurement of therapies) and continued telemetry via attribution cell. Cohesion backstop held locally but money slow; US materials catalyst breakthrough underlined frontier gap. Polls slipped back toward hostility.
```
